Here we report a new GWAS, a meta-analysis with previous GWAS and a replication series, totaling 7,319 TGCT cases and 23,082 controls. We identify 19 new TGCT risk loci, roughly doubling the number of known TGCT risk loci to 44. By performing in situ Hi-C in TGCT cells, we provide evidence for a network of physical interactions among all 44 TGCT risk SNPs and candidate causal genes. Our findings implicate widespread disruption of developmental transcriptional regulators as a basis of TGCT susceptibility, consistent with failed primordial germ cell differentiation as an initiating step in oncogenesis 1 . Defective microtubule assembly and dysregulation of KIT-MAPK signaling also feature as recurrently disrupted pathways. Our findings support a polygenic model of risk and provide insight into the biological basis of TGCT.
TGCT is the most common cancer in men aged 18-45, with more than 52,000 new cases diagnosed annually worldwide 2 . The development of TGCT is strongly influenced by inherited genetic factors, which contribute to nearly half of all disease risk 3 and are reflected in the four-to eightfold increased risk in siblings of cases [4] [5] [6] [7] . Our understanding of TGCT susceptibility has been transformed by recent GWAS, which have so far identified 25 independent risk loci for TGCT [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Although projections indicate that additional risk variants for TGCT can be discovered by GWAS 19 , studies to date have been based on comparatively small sample sizes that have had limited power to detect common risk variants 20 .
To gain a more comprehensive insight into TGCT etiology, we performed a new GWAS with substantially increased power, followed by a meta-analysis with existing GWAS and replication genotyping (totaling 7,319 cases and 23,082 controls). Here we report both the discovery of 19 new TGCT susceptibility loci and refined risk estimates for the previously reported loci. In addition, we have investigated the gene regulatory mechanisms underlying the genetic associations observed at all 44 TGCT GWAS risk loci by performing in situ chromosome conformation capture in TGCT cells (Hi-C) to characterize chromatin interactions between predisposition SNPs and target genes, integrating these data with a range of publicly available TGCT functional genomics data.
We conducted a new GWAS using the OncoArray platform (3,206 UK TGCT cases and 7,422 UK controls), followed by a meta-analysis combining the two largest published TGCT GWAS data sets 11, 16 (986 UK cases and 4,946 UK controls and 1,327 Scandinavian cases and 6,687 Scandinavian controls) (Fig. 1) . To increase genomic resolution, we imputed >10 million SNPs using the 1000 Genomes Project as a reference panel. Quantile-quantile (Q-Q) plots for SNPs with minor allele frequency (MAF) >5% after imputation did not show evidence of substantive over-dispersion (λ 1,000 = 1.03, Supplementary Fig. 1 ).
Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor 1 1 3 4 VOLUME 49 | NUMBER 7 | JULY 2017 Nature GeNetics l e t t e r S We derived joint odds ratios (ORs) and 95% confidence intervals (CIs) under a fixed-effects model for each SNP with MAF >0.01. Finally, we sought validation of 37 SNPs associated at P < 5.0 × 10 −6 , which did not map to known TGCT risk loci and displayed a consistent OR across all GWAS data sets, by genotyping an additional 1,801 TGCT cases and 4,027 controls from the UK. After meta-analysis of the three GWAS and replication series, we identified genome-wide significant associations (i.e., P < 5 × 10 −8 ) at 19 new loci ( Table 1) . We found no evidence for significant interactions between risk loci.
To the extent that they have been deciphered, many GWAS risk loci map to noncoding regions of the genome and influence gene regulation. Across the 44 independent TGCT risk loci (19 new and 25 previously reported), we confirmed a significant enrichment of enhancer-or promoter-associated histone marks, including monoand trimethylation of histone H3 at Lys34 (H3K4me1 and H3K4me3, respectively) and acetylation of H3 Lys9 (H3K9ac), using available chromatin immunoprecipitation (ChIP)-seq data from the TGCT cell line NTERA2 (P < 5.0 × 10 −3 ) (Supplementary Table 1 ). Moreover, this enrichment showed tissue specificity when compared to 41 other cell lines from the ENCODE 21 project (Supplementary Fig. 2 ). These New loci (n = 19) discovered through this study are marked in bold. RAF, risk allele frequency; P trend , P value for trend, via logistic regression; P meta , P value for fixed effects meta-analysis; I 2 , heterogeneity index (0-100).
l e t t e r S l e t t e r S TGCT (TCGA), acknowledging that the latter may be affected by the issue of tumor purity, in addition to dysregulated gene expression that typifies cancer. Accepting this limitation and that further validation may be required, we conducted eQTL analysis in both data sets on the basis of the established network of enhancer and promoter variants to maximize our ability to find statistically significant associations after correcting for multiple testing. We additionally annotated risk loci with variants predicted to disrupt binding motifs of germ cell-specific transcription factors (TFs) (Online Methods). Finally, we denoted direct promoter variants and nonsynonymous coding mutations for genes within the 44 risk loci ( Table 2 and Fig. 2) .
observations support the assertion that the TGCT predisposition loci influence risk through effects on cis-regulatory networks and are involved in transcriptional initiation and enhancement. As genomic spatial proximity and chromatin looping interactions are fundamental for regulation of gene expression, we performed in situ capture Hi-C of promoters in NTERA2 cells to link risk loci to candidate target genes. We also sought to gain insight into the possible biological mechanisms for the associations by performing tissue-specific expression quantitative trait loci (eQTL) analysis for all risk SNP and target gene pairs ( Supplementary Fig. 3 and Supplementary Table 2) . We analyzed RNA-seq data from both normal testis (GTEx project) 22 and Figure 2 Circos plot of integrated functional analysis for all 44 TGCT risk loci. Innermost ring represents the presence of a Hi-C contact in the NTERA2 cell line; the next four rings are narrow-peak histone ChIP-seq tracks for NTERA2; the sixth ring represents −log(P) of TGCT risk association from the Oncoarray GWAS data, with green line denoting genome-wide significance, and the seventh ring (outermost) is the functional annotation and classification of candidate causal genes.
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VOLUME 49 | NUMBER 7 | JULY 2017 Nature GeNetics l e t t e r S Although preliminary and requiring functional validation, our analysis indicated three candidate disease mechanisms across the 44 loci. First, 10 of the risk loci contain candidate genes linked to developmental transcriptional regulation, as evidenced by Hi-C looping interactions (at 8p23.1 and 20q13.2), eQTL effects (at 4q22.3 and 8p23.1), promoter variants (at 8q13.3, 9p24.3, 12q15, 17q12 and 19p12) and coding variants (at 2p13.3 and 16q24.2) ( Table 2) . Notably, the new TGCT risk locus at 8p23.1 features a looping chromatin interaction from risk SNP rs17153755 to the promoter of GATA4, which is supported by an overlapping predicted strong enhancer region and a nominal eQTL effect (TCGA data, P = 3.1 × 10 −2 ) (Fig. 3a) . The rs17153755 risk allele was associated with downregulation of GATA4 expression, consistent with the hypothesized role of GATA4 as a tumor suppressor gene 23, 24 . In addition, the risk locus at 16q24.2 contains only a single gene, ZFPM1 (alias FOG, Friend of GATA1), which encodes an essential regulator of GATA1 (ref. 25) , in which we noted a predicted damaging 26 missense polymorphism (rs3751673, NP_722520.2:p.Arg22Gly). GATA transcription factors are expressed throughout postnatal testicular development 27 and have a key role in ensuring correct tissue specification and differentiation 28 . We also observed promoter variants at 8q13.3 and 9p24.3, providing support for the role of PRDM14 and DMRT1, respectively, in TGCT oncogenesis, both of which encode important transcriptional regulators of germ cell specification and sex determination [29] [30] [31] [32] . Of final note, 
l e t t e r S
the new locus at 20q13.2 was characterized by a predicted disrupted POU5F1 binding motif, together with a looping Hi-C contact from risk SNP rs12481572 to the promoter of SALL4, a gene associated with the maintenance of pluripotency in embryonic stem cells 33 . Second, candidate genes with roles related to microtubule or chromosomal assembly were implicated at five TGCT risk loci, supported by Hi-C looping interactions (at 1q22 and 15q25.2), eQTL effects (at 15q25.2 and 17q22), promoter variants (at 1q22 and 4q24) and coding variants (at 21q22.3) . Notably, at locus 17q22, we observed a promoter variant (rs302875) that displays a strong eQTL effect (GTEx data, P = 4.9 × 10 −7 ) on TEX14 (testis-expressed 14), which encodes an important regulator of kinetochore-microtubule assembly in testicular germ cells 14, 34, 35 . At new risk locus 15q25.2, we identified a nominal eQTL association (rs2304416, TCGA data, P = 3.2 × 10 −2 ) and accompanying chromatin looping interaction with mitotic spindle assembly related gene WDR73 (ref. 36) (Fig. 3b) . WDR73 encodes a protein with a crucial role in the regulation of microtubule organization during interphase 37 , and biallelic mutations cause GallowayMowat Syndrome, a human disorder characterized by nephrosis and neuronal dysmigration. Finally, the analysis also highlighted microtubule assembly-related genes PMF1, CENPE and PCNT [38] [39] [40] [41] as candidates at 1q22, 4q24 and 21q22.3, respectively.
Third, the central role of KIT-MAPK signaling in TGCT oncogenesis was further supported at four loci, by Hi-C looping interactions (at 11q14.1 and 15q22.31), eQTL effects (at 6p21.31) and promoter variants (at 6p21.31, 11q14.1 and 15q22.31). Recent tumor sequencing studies have established that KIT is the major somatic driver gene for TGCT 42 , and a relationship between the previously identified risk SNP rs995030 (12q21) and KITLG expression has been demonstrated through allele-specific p53 binding 43 . We report a new locus at 15q22.31, containing a variant within the promoter of MAP2K1 (Fig. 3c) , which raises the prospect of further elucidating mechanisms of KIT-MAPK signaling in driving TGCTs. MAP2K1 (alias MEK1) is downstream of c-Kit, and MEK1 inhibition slows primordial germ cell growth in the presence of KIT ligand 44 . If MAP2K1 is confirmed as a causal gene at 15q22.31, the study of somatic KIT mutational status in patients carrying the risk allele at 15q22.31 should be highly informative. In addition, within the 11q14.1 risk locus, we identified a candidate promoter variant for GAB2, which encodes a docking protein for signal transduction to MAPK and PI3K pathways that interacts directly with KIT 45 . Finally, we identified both a candidate promoter variant and a nominal eQTL effect for BAK1 (6p21.31) (TCGA data, P = 1.9 × 10 −2 ), which encodes an apoptosis-regulating protein that binds with KIT 40 . While we have sought to decipher the functional basis of risk loci on the basis of the cumulative weight of evidence across eQTL, Hi-C and ChIP-seq data, a limitation has been reliance on relatively small sample size for eQTL analysis. Access to larger eQTL data sets in testicular tissue is likely in the future to address this deficiency, enabling a better definition of the causal basis of TGCT risk at each locus.
The 44 risk loci that have been identified for TGCT collectively account for 34% of the (father-to-son) familial risk and hence have potential clinical utility for personalized risk profiling. To assess this potential, we constructed polygenic risk scores (PRSs) for TGCT, considering the combined effect of all risk SNPs modeled under a log-normal relative risk distribution. Using this approach, the men in the top 1% of genetic risk had a relative risk of 14, which translates to a 7% lifetime risk of TGCT (Supplementary Fig. 4) .
In summary, we have performed a new TGCT GWAS, identifying 19 new risk loci for TGCT, approximately doubling the number of previously reported SNPs. Using capture Hi-C, we have generated a chromatin interaction map for TGCT, providing direct physical interactions between noncoding risk SNPs and target gene promoters. Moreover, integration of these data, together with ChIP-seq chromatin profiling and RNA-seq eQTL analysis, accepting certain caveats, has allowed us to gain preliminary but unbiased tissue-specific insight into the biological basis of TGCT susceptibility. This analysis suggests a model of TGCT susceptibility based on transcriptional dysregulation, which is likely to contribute to the developmental arrest of primordial germ cells, coupled with chromosomal instability through defective microtubule function and accompanied upregulation of KIT-MAPK signaling.
URLs. TCGA Research Network, http://cancergenome.nih.gov/.
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Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. The results published here are based in part on data generated by the TCGA Research Network. This study makes use of data generated by the Wellcome Trust Case Control Consortium 2 (WTCCC2). We acknowledge the contribution of E. Rapley and M. Stratton to the generation of previously published UK GWAS case data. We thank all the individuals who took part in these studies and all the researchers, clinicians, technicians and administrative staff who have enabled this work to be carried out. We acknowledge National Health Service funding to the National Institute for Health Research Biomedical Research Centre. We thank the UK Genetics of Prostate Cancer Study (UKGPCS) study teams for the recruitment of the UKGPCS controls. Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) (U19 CA 148537 for Elucidating Loci Involved in Prostate cancer Susceptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I). Additional analytical support was provided by NIH NCI U01 CA188392. The PRACTICAL consortium was supported by Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692 and C16913/A6135; the European Commission's Seventh performed using five cycles to minimize PCR duplicates. 2 × 100-bp sequencing was performed using Illumina HiSeq2000 or 2500 technology. The HiCUP pipeline 62 was used to process raw sequencing reads, map di-tag positions against the reference human genome and remove duplicate reads. The protocol was performed for two independent NTERA2 cell culture replicates, with cells obtained from the laboratory of Janet Shipley (The Institute of Cancer Research, London, UK) and their identity independently confirmed through STR typing at an external laboratory (Public Health England, Porton Down, UK). Cells were tested and found to be negative for mycoplasma contamination. Both Hi-C libraries achieving the following quality control thresholds: >80% reads uniquely aligning, >80% valid pair rate, >85% unique di-tag rate and >80% of interactions being cis (Supplementary Table 4) . Statistically significant interactions were called using the CHiCAGO pipeline 63 , with both cell culture replicates processed in parallel to obtain a unique list of reproducible NTERA2 contacts. Stability of results across replicates was also verified by processing each sample individually and comparing the significance scores of called interactions; strong correlation was observed between the replicates (r = 0.8, P < 5.0 × 10 −10 , Supplementary Fig. 7 ). Interactions with a −log(weighted P value) > 5 were considered significant. To avoid short-range proximity bias, interactions of <40 kb were excluded. The distribution of interaction distances closely matched the prior published data set of Misfud et al. 61 ( Supplementary Fig. 8) . A Hi-C track plotting read pair counts per HindIII fragment has been added to region plot figures to demonstrate the underlying signal strength of significant Hi-C contacts.
3C validation. 3C was used to validate selected chromatin interactions detected by CHi-C (3p24.3, 4q24, 11q14.1, 15q22.31, 15q25.2, 16q12.1, and 16q23.1) (Supplementary Fig. 9 and Supplementary Table 5 ). Three cell culture replicates of in situ 3C libraries were prepared using NTERA2 cells. Cell pellets were cross-linked, digested with HindIII, and ligated. Libraries were purified by phenol-chloroform extraction.
For each locus, one or more bacterial artificial chromosomes (BACs; Source BioScience) were used as an internal standard (Supplementary Table 6 ). Clones were streaked and grown before extracting DNA using a QIAGEN Plasmid Maxi Kit, which was purified by phenol-chloroform extraction. In loci covered by more than one clone, equimolar solutions of clones were prepared. Randomly ligated 3C libraries were generated for each BAC or equimolar solution of BACs.
Unidirectional primer pairs were designed to amplify ligation junctions of the bait and other interacting HindIII fragment (promoter-element, P-E) and around the bait and a flanking control HindIII fragment in between the promoter and distal element (promoter-control, P-C) using Primer3 (Supplementary Tables 7 and 8 ) 64 . Regions were amplified using both P-E and P-C primer pairs in BAC and NTERA2 libraries using a QIAGEN Multiplex PCR Kit. 5 ng and 100 ng of BAC and NTERA2 library template DNA, respectively, were amplified using the following procedure: initial 15 min denaturation at 95 °C followed by 38 cycles of 94 °C for 0.5 min, annealing temperature specific to primer pair for 1.5 min, 72 °C extension for 1.5 min, followed by a final 10 min extension at 72 °C. 5 µl of each PCR reaction was visualized on 2% agarose gels stained with ethidium bromide. ImageJ 65 was used to quantify intensities of PCR products and normalize for differential primer efficiency by comparing to equimolar BAC PCR products. P-E fragments were Sanger sequenced in NTERA2 libraries to confirm fragments visualized on agarose gels as expected (Supplementary Fig. 10 ).
Chromatin state annotation. We used ChromHMM 66 to infer chromatin states by integrating information on histone modifications and DNaseI hypersensitivity data to identify combinatorial and spatial patterns of epigenetic marks. Aligned next-generation sequencing reads from ChIP-seq and DNAse-seq experiments on the NTERA2 cells were downloaded from ENCODE 21 . Read-shift parameters for ChIP-seq data were calculated using PHANTOMPEAKQUALTOOLS. Genome-wide signal tracks were binarized (including input controls for ChIP-seq data), and a set of learned models were generated using ChromHMM software 66 . The parameters of the highest scoring model were retained and model states were iteratively reduced down from 30 to 5 states. A 27-state model found to be stable and was subsequently used for segmenting the genome at 200-bp resolution (Supplementary Fig. 11 ).
Expression quantitative trait locus analysis. We investigated for evidence of association between the SNPs at each locus and tissue-specific changes in gene expression using two publicly available resources: (i) RNA-seq and Affymetrix 6.0 SNP data for 150 TGCT patients from The Cancer Genome Atlas and (ii) normal testicular tissue data from GTEx from 157 samples 22 . Associations between normalized RNA counts per-gene and genotype were quantified using R package 'Matrix eQTL' . Box plots of all eQTL associations are presented in Supplementary Figure 3 , and the tissue in which the association was observed (TGCT or normal testis), along with any other tissues resulting in a positive association, are denoted in Supplementary Table 2 . To reduce multiple testing, association tests were only performed between SNP and gene pairs where either: (i) a direct promoter variant was observed (as per column six of Table 2 ) or (ii) a Hi-C contact to a gene promoter was observed (as per column nine of Table 2 ), together with functionally active chromatin (as per column seven of Table 2 ). The SNP used for testing at each locus was selected based on the closest available proxy (highest R 2 ) to the functional variant (i.e., the promoter or Hi-C contact variant), rather than using the sentinel SNP with the strongest TGCT association. Finally, as a comparison all possible gene-variant eQTL combinations were also tested at each locus (ignoring the functional Hi-C, promoter and CHiP-seq data), to provide a reference overview of all possible eQTL associations at each locus (Supplementary Table 9 ).
Transcription factor binding motif analysis. The impact of variants on regulatory motifs was assessed for a set of transcription factors (TFs) associated with germ cell development. A germ cell specific TF set was used, rather than all TFs globally, to provide increased specificity. An OMIM 67 searchterm-driven method was used to define the germ cell development TF set, using the following search terms: 'germ cell AND development AND transcription factor' (n = 46). The TF list was then intersected with predicted TF binding motifs based on a library of position weight matrices computed by Kheradpour and Kellis 68, 69 . The intersected data set contained motif position data for 10 TFs: DMRT1, GATA, KLF4, LHX8, NANOG, POU5F1, PRDM1, SOX2, SOX9 and CTCF. To validate the specificity of these motifs for TGCT, we conducted variant set enrichment analysis, using the same method as detailed above (based on ref. 59 ), which confirmed enrichment for disruption of these 10 motifs in the 44 TGCT risk loci compared to the null distribution (Supplementary Table 10 ).
Integration of functional data. For the integrated functional annotation of risk loci, LD blocks were defined as all SNPs in r 2 > 0.8 with the sentinel SNP. Risk loci were then annotated with six types of functional data: (i) presence of a Hi-C contact linking to a gene promoter, (ii) presence of an eQTL, (iii) presence of a ChIP-seq peak, (iv) presence of a disrupted transcription factor binding motif, (v) presence of a variant within a gene promoter boundary, with boundaries defined using the Ensembl regulatory build 70 , (vi) presence of a nonsynonymous coding change. Candidate causal genes were then assigned to TGCT risk loci using the target genes implicated in annotation tracks (i), (ii), (v) and (vi). Where the data supported multiple gene candidates, the gene with the highest number of individual functional data points was assigned to be the candidate. Where multiple genes have the same number of data points, all genes are listed. Direct nonsynonymous coding variants were allocated additional weighting. Competing mechanisms for the same gene (for example, both coding and promoter variants) were allowed. Data availability. Case OncoArray GWAS data and the Hi-C data set used in this paper have been deposited in the European Genome-phenome Archive (EGA) under accession codes EGAS00001001836 and EGAS00001001930, respectively.
